Original video by AstraZeneca: https://medicines.astrazeneca.co.uk/home/cardiovascular/brilique/mode-of-action.html. Brilinta/Brilique (ticagrelor) is a P2Y12 platelet inhibitor indicated to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI). For at least the first 12 months following ACS, it is superior to clopidogrel. Brilinta/Brilique also reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS. Brilinta/Brilique contains ticagrelor, a cyclopentyltriazolopyrimidine, inhibitor of platelet activation and aggregation mediated by the P2Y12 ADP-receptor. Ticagrelor and its major metabolite reversibly interact with the platelet P2Y12 ADP-receptor to prevent signal transduction and platelet activation. Ticagrelor and its active metabolite are approximately equipotent.